Company Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases.
It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha.
In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer.
It has collaboration and license agreements with D. E.
Shaw Research, LLC to research certain biological targets through the use of D. E.
Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib.
The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.
Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 261 |
| CEO | Sanjiv Patel |
Contact Details
Address: 399 Binney Street, 2nd Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617 370 8837 |
| Website | relaytx.com |
Stock Details
| Ticker Symbol | RLAY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001812364 |
| CUSIP Number | 75943R102 |
| ISIN Number | US75943R1023 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | Chief Executive Officer, President and Director |
| Thomas Catinazzo | Chief Financial Officer |
| Brian R. Adams J.D. | Chief Legal Officer and Secretary |
| Peter Rahmer | Chief Corporate Development Officer |
| Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research and Development |
| Dorothee Kern Ph.D. | Founder |
| Dr. David Elliot Shaw Ph.D. | Founder |
| Matthew P. Jacobson Ph.D. | Founder |
| Jim Watters Ph.D. | Chief Scientific Officer |
| Dr. Beni B. Wolf M.D., Ph.D. | Chief Medical Officer and Head of Precision Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 5, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | 144 | Filing |
| Apr 28, 2025 | 144 | Filing |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 27, 2025 | 144 | Filing |